Analyst Price Targets — NICE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 30, 2026 10:04 am | Timothy Horan | Oppenheimer | $150.00 | $106.81 | TheFly | Nice upgraded to Outperform from Perform at Oppenheimer |
| September 24, 2026 12:03 pm | — | RBC Capital | $145.00 | $115.85 | TheFly | Nice price target raised to $145 from $130 at RBC Capital |
| August 6, 2026 1:23 pm | — | D.A. Davidson | $115.00 | $98.16 | TheFly | Nice price target raised to $115 from $110 at DA Davidson |
| July 21, 2026 6:03 am | Elizabeth Porter | Morgan Stanley | $111.00 | $101.34 | StreetInsider | Morgan Stanley Downgrades NICE Systems Ltd (NICE) to Equalweight |
| June 18, 2026 10:14 am | — | D.A. Davidson | $110.00 | $83.15 | TheFly | Nice upgraded to Buy from Neutral at DA Davidson |
| June 10, 2026 12:51 pm | — | Wedbush | $100.00 | $88.74 | TheFly | Nice price target lowered to $100 from $120 at Wedbush |
| May 11, 2026 12:18 pm | — | Morgan Stanley | $130.00 | $91.16 | TheFly | Nice price target lowered to $130 from $148 at Morgan Stanley |
| May 7, 2026 1:31 pm | — | RBC Capital | $130.00 | $98.00 | TheFly | Nice price target lowered to $130 from $150 at RBC Capital |
| February 23, 2026 11:44 am | James Fish | Piper Sandler | $124.00 | $117.69 | TheFly | Nice price target raised to $124 from $122 at Piper Sandler |
| February 20, 2026 1:50 pm | — | Morgan Stanley | $148.00 | $116.37 | TheFly | Nice price target lowered to $148 from $160 at Morgan Stanley |
Latest News for NICE
Parnassus Value Equity Fund (Investor Shares) returned -1.38% (net of fees) for the quarter, underperforming the Russell 1000 Value Index's 2.61%. Top contributors include Thermo Fisher, CME Group, NICE, Willis Towers Watson and Verizon. Bottom contributors include Cummins, Applied Materials, Brookfield Renewable, Home Depot and AstraZeneca.
Nice (NICE) concluded the recent trading session at $122.41, signifying a +1.02% move from its prior day's close.
Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZIÂ (durvalumab) in combination with neoadjuvant enfortu
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Zacks.com users have recently been watching Nice (NICE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.